A bitter management shake-up. Angry public outbursts. A “narcissistic” pastor whose word is gospel. What in God’s name is ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed ...

Merck recently experienced a significant corporate governance event when multiple shareholder proposals were announced, with the company recommending against them for the upcoming annual meeting.

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Stocks recently featured in the blog include Merck MRK and AbbVie ABBV. Here are highlights from Tuesday’s Analyst Blog: Merck and AbbVie are leading pharmaceutical companies with strong ...

Cyprumed may receive up to $493 million in milestone payments from Merck for peptide drug delivery tech. Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist.

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. Merck has entered an exclusive licensing ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval ...